Form 8-K - Current report:
SEC Accession No. 0001493152-24-043670
Filing Date
2024-11-05
Accepted
2024-11-05 16:37:36
Documents
16
Period of Report
2024-11-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39133
2 ex99-1.htm EX-99.1 2468
3 form8-k_001.jpg GRAPHIC 13762
4 ex99-1_001.jpg GRAPHIC 1536346
  Complete submission text file 0001493152-24-043670.txt   2370426

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE lpcn-20241105.xsd EX-101.SCH 3015
6 XBRL LABEL FILE lpcn-20241105_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE lpcn-20241105_pre.xml EX-101.PRE 24165
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3681
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 241428092
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)